Delivery Order SPE2DB20D2002-SPE2DB21FL51G
- Not listed
- This federal contract award, valued at $1,660.80, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Mupirocin 2% Ointment, a topical antibiotic medication, to support military healthcare programs. The contract has an ultimate completion date of May 30, 2024 and is structured as a Firm Fixed Price Delivery Order, without any set-aside designation....
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,250.04, is a delivery order for the supply of Mupirocin 2% Ointment. It is a firm fixed-price contract with a performance period ending on May 28, 2025. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The $1,358.08 delivery order is for Mupirocin 2% Cream, 15 gram, a topical antibiotic ointment. The contract has a firm fixed price pricing type and an ultimate completion date of December 13, 2021. This contract is not designated with any set-aside requirements, indicating full and open competition. Amerisourcebergen Drug Corp holds a...
- This federal contract award, valued at $1,934.68, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Mupirocin 2% Ointment, a topical antibiotic medication, with an ultimate completion date of August 17, 2023. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,356.79 firm fixed-price delivery order is for the supply of 15g tubes of Mupirocin 2% cream, a topical antibiotic medication. The contract has an ultimate completion date of April 5, 2023. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The $3,203 firm-fixed-price contract is for the delivery of Mupirocin 2% Ointment 22GM, a topical antibiotic medication. The order has a period of performance through September 26, 2023. Amerisourcebergen Drug Corp holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for...
- This federal contract award, with ID SPE2DB20D1004|SPE2DB25FNEGM, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, which is a Delivery Order with a Firm Fixed Price pricing type, is for the delivery of Mupirocin 2% Cream 15GM. The contract has a ceiling value of $1,911.60 and an ultimate completion date of January 17, 2025. This contract award is not associated with a set-aside...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation for the supply of Mupirocin 2% ointment, a topical antibiotic medication. The contract has a firm fixed price of $3,334.38 and an ultimate completion date of October 8, 2024. AmerisourceBergen, a major pharmaceutical distributor, is providing these medical supplies to support military treatment facilities and other federal healthcare providers. The contract is not designated as a...
- This federal contract award is for the delivery of Mupirocin 2% cream, a topical antibiotic medication, to the Defense Logistics Agency (DLA). The $1,096.68 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, on August 29, 2023 with a completion date of August 30, 2023. The contract is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,404.12 firm fixed-price contract is for the supply of Mupirocin 2% Ointment 22g to support federal healthcare programs. The contract has an ultimate completion date of February 7, 2025 and is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
- SPE2DB20D2002Indefinite Delivery Contract
- SPE2DB20D2002-SPE2DB21FL51GDelivery Order
This federal contract award, with an ID of SPE2DB20D2002|SPE2DB21FL51G, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,424.71 Firm Fixed Price contract is for the delivery of Mupirocin 2% Ointment, a prescription topical antibiotic medication. This award is a Delivery Order placed against AmerisourceBergen's Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. The IDC enables the DLA to efficiently procure a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This contract award does not have a set-aside designation, indicating full and open competition. AmerisourceBergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which also holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 8/11/21 |